Bullish Sentiments are Rising for Fate Therapeutics Stock Price
Fate Therapeutics Inc. (NASDAQ:FATE) shares continue to extend the momentum in Tuesday trade, supported by investors bullish bets on its future fundamentals and advancement in key pipeline products. Fate Therapeutics shares improved 14% in Tuesday’s ... [Read]
Why Inovio Pharmaceuticals is Up Nearly 30% Today
Sure, most of the world might be focusing on the fact that Bitcoin climbed above the $11,000 mark today, despite Goldman Sachs (NYSE:GS) sending out a warning to investors that the digital currency is a ... [Read]
Idera Pharmaceuticals Stock Plunges 20% – Here’s Why
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) is under investigation by Levi & Korsinsky, LLP, an established firm in securities litigation. What happened? Earlier in the day, it was announced that Idera Pharmaceuticals would be merging with BioCryst ... [Read]
Are Companies Looking at Acorda Therapeutics as a Potential Takeover Target?
Two months ago, New York-based Acorda Therapeutics (NASDAQ:ACOR) had to discard its late-stage drug tozadenant due to five patients passing away in a clinical trial. At the time, this looked like it was going to ... [Read]
Diffusion Pharmaceuticals Discloses $12M Underwritten Public Offering, Stock Plunges Nearly 40%
Last week, Diffusion Pharmaceuticals (NASDAQ:DFFN), a clinical-stage biotechnology company based in Charlottesville, Virginia, soared nearly 40% on the market after CEO David Kalergis presented an overview of the company to the crowd at San Francisco’s ... [Read]
Hot Stocks Today: Aeterna Zentaris Inc. Soars on Huge Drug Deal
Shares in Aeterna Zentaris Inc. (TSX:AEZS) (NASDAQ:AEZS) have shot up 37% today as values rose from $2.08 yesterday closing time to a peak of $2.85 at 9:45 EST this morning. This comes on the heels of a ... [Read]
Sangamo Expansion Strategies Are Working, Shares Rallied Above 300% Last Year
With a market capitalization of $1.5 billion, Sangamo Therapeutics (NASDAQ:SGMO) continues to impress investors with its expansion strategies. Sangamo recently announced its partnership with Pfizer (NYSE:PFE), with an aim to develop a gene therapy to treat ... [Read]
Top Performer Marinus Pharmaceuticals Has More Upside
Marinus Pharmaceuticals (NASDAQ:MRNS) holds the first spot in terms of its stock price performance last year. MRNS stock rallied above 800% before the latest selloff. Marinus stock price soared from $1.25 at the beginning of ... [Read]
Does the Amarin Stock Rally Offer a Selling Opportunity?
Amarin Corporation (NASDAQ:AMRN) investors are cheering several impressive reports related to the company’s financial and operational performance, which has led the stock price to rally above 29% in the last month alone. However, traders are ... [Read]
Concert Pharmaceuticals Seeing Red; Stock Down Nearly 30% After PTAG Rejects its Grant
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) is seeing red. The market closes in twenty minutes, which doesn’t give the Lexington, Massachusetts-based company enough time to try and make a comeback. As of this writing, Concert Pharmaceuticals is ... [Read]